Christiane Hartog1, Konrad Reinhart. 1. Department of Anaesthesiology and Intensive Care Medicine, Friedrich Schiller University, Erlanger Allee 101, 07747 Jena, Germany.
Abstract
PURPOSE: To describe the risk-benefit profile of hydroxyethyl starch (HES). METHODS: Narrative review. RESULTS: (1) EFFICACY: no single clinical study or systemic review has shown that administration of any HES solution confers a clinically relevant benefit compared to crystalloids in critically ill patients or surgical patients in need of volume replacement. Contrary to beliefs expecting a ratio of 4:1 or more for crystalloid to colloid volume need, recent studies of goal-directed resuscitation observed much lower ratios of between 1 and 1.6. (2) SAFETY: HES administration is associated with coagulopathy, nephrotoxicity, pruritus and increased long-term mortality. Clinical studies claiming that modern HES 130/0.4 is safe have serious methodological drawbacks and do not adequately address the safety concerns. CONCLUSIONS: Given the complete lack of superiority in clinical utility studies and the wide spectrum of severe side effects, the use of HES in the ICU should be stopped. The belief that four times as much crystalloid as colloid fluid volume is needed for successful resuscitation is being seriously questioned.
PURPOSE: To describe the risk-benefit profile of hydroxyethyl starch (HES). METHODS: Narrative review. RESULTS: (1) EFFICACY: no single clinical study or systemic review has shown that administration of any HES solution confers a clinically relevant benefit compared to crystalloids in critically illpatients or surgical patients in need of volume replacement. Contrary to beliefs expecting a ratio of 4:1 or more for crystalloid to colloid volume need, recent studies of goal-directed resuscitation observed much lower ratios of between 1 and 1.6. (2) SAFETY: HES administration is associated with coagulopathy, nephrotoxicity, pruritus and increased long-term mortality. Clinical studies claiming that modern HES 130/0.4 is safe have serious methodological drawbacks and do not adequately address the safety concerns. CONCLUSIONS: Given the complete lack of superiority in clinical utility studies and the wide spectrum of severe side effects, the use of HES in the ICU should be stopped. The belief that four times as much crystalloid as colloid fluid volume is needed for successful resuscitation is being seriously questioned.
Authors: Bridget A Wills; M Dung Nguyen; T Loan Ha; T H Tam Dong; T N Thuy Tran; T T Minh Le; V Diet Tran; T Hao Nguyen; V Chau Nguyen; Kasia Stepniewska; Nicholas J White; Jeremy J Farrar Journal: N Engl J Med Date: 2005-09-01 Impact factor: 91.245
Authors: Joachim Boldt; Thorsten Brenner; Andreas Lehmann; Johannes Lang; Bernhard Kumle; Christiane Werling Journal: Intensive Care Med Date: 2003-03-29 Impact factor: 17.440
Authors: J Verheij; A van Lingen; P G H M Raijmakers; E R Rijnsburger; D P Veerman; W Wisselink; A R J Girbes; A B J Groeneveld Journal: Br J Anaesth Date: 2005-11-25 Impact factor: 9.166
Authors: Shadan Li; Bin Liu; Qiunong Guan; Irina Chafeeva; Donald E Brooks; Christopher Yc Nguan; Jayachandran N Kizhakkedathu; Caigan Du Journal: Am J Transl Res Date: 2017-02-15 Impact factor: 4.060
Authors: Massimo Antonelli; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; J Randall Curtis; Daniel De Backer; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Patricia Rocco; Jean-François Timsit; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2012-01-20 Impact factor: 17.440
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2010-01-28 Impact factor: 17.440